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Insulin transcriptionSirtuin 1 (SIRT1), a nicotinamide adenosine dinucleotide-dependent histone deacetylase, is an important reg-
ulator of energy homeostasis in response to nutrient availability. In pancreatic β-cells, SIRT1 has been shown
to up-regulate insulin secretion in response to glucose stimulation. However, the potential roles of SIRT1 in
islet β-cells against lipotoxicity remain poorly understood. Here, we demonstrated that SIRT1 mRNA and pro-
tein expressions were markedly reduced in the islets isolated from rats infused with 20% Intralipid for 24 h.
Long-term exposure to 0.4 mmol/L palmitate also decreased SIRT1 expression in cultured INS-1 cells and iso-
lated rat islets, which was prevented by 10 μmol/L resveratrol, a SIRT1 agonist. In addition, resveratrol im-
proved glucose-stimulated insulin secretion decreased by palmitate, which was abrogated by EX527, a
speciﬁc SIRT1 inhibitor. Furthermore, inhibition of SIRT1 activity by EX527 or a knockdown of SIRT1
suppressed insulin promoter activity, along with decreased insulin, v‐maf musculoaponeurotic ﬁbrosarcoma
oncogene homolog A (MafA), and NK6 homeodomain 1 (NKX6.1) mRNA expressions. Activation of SIRT1 by
resveratrol or overexpression of SIRT1 antagonized palmitate-inhibited insulin transcriptional activity. SIRT1
overexpression exerted an additive effect on pancreatic and duodenal homeobox 1 (PDX1)-stimulated insulin
promoter activity and abolished forkhead box O1 protein (FOXO1)-decreased insulin transcriptional activity.
Resveratrol reversed FOXO1 nuclear translocation induced by palmitate. Our ﬁndings indicate that SIRT1 pro-
tects against palmitate-induced β-cell dysfunction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Type 2 diabetes mellitus is characterized by insufﬁcient insulin se-
cretion in response to elevations of plasma glucose, and excessive cir-
culating lipid levels have been suggested to contribute, in conjunction
with chronic hyperglycemia, to the progressive deterioration of β cell
function in this disease [1,2]. Acute exposure of the β cell to free fattyc and duodenal homeobox 1;
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rights reserved.acid (FFA) results in an increase of insulin release, whereas chronic
exposure leads to desensitization and suppression of secretion [3,4].
Evidence also indicates that elevated FFA inhibits insulin biosynthesis
and decreases cell viability [5–7]. However, the mechanisms underly-
ing the detrimental impact of FFAs on the β cell are still incompletely
understood.
The NAD+-dependent deacetylase Sir2 extends the life span of a
lower eukaryote [8]. Its mammalian ortholog sirtuin 1 (SIRT1) plays piv-
otal roles in various physiological processes including cell cycle regula-
tion, gene silencing, metabolism, and inﬂammation [9–11]. In skeletal
muscle, SIRT1 is suggested to interact with and deacetylate peroxisome
proliferator-activated receptor gamma coactivator 1 (PGC-1) to enhance
mitochondrial biogenesis [12]. It has been shown that SIRT1 regulates
glucose and lipid homeostasis through deacetylating signal transducer
and activator of transcription 3 (STAT3) and liver X receptor (LXR) in
liver [13,14]. Moreover, glucose-stimulated insulin secretion (GSIS) in is-
lets of SIRT1-knockoutmice is blunted [15], whereas GSIS is enhanced in
β-cell‐speciﬁc SIRT1-overexpressing mice [16], suggesting that SIRT1
functions as a positive regulator of insulin secretion and maintenance
of β cell function. Sun et al. [17] found that palmitate decreased SIRT1
protein expression in C2C12 myotubes and overexpression of SIRT1
1816 L. Wu et al. / Biochimica et Biophysica Acta 1822 (2012) 1815–1825improved palmitate-induced insulin resistance. But whether SIRT1 could
protect against lipotoxicity in β cells remains elusive.
In the present study, we showed that fatty acids decreased SIRT1 ex-
pression in INS-1 insulinoma cells and isolated rat islets in vivo and
in vitro. Resveratrol, a SIRT1 agonist, ameliorated palmitate-suppressed
insulin secretion. Therefore, we further investigated the effect of SIRT1
on insulin transcriptional activity under lipotoxic conditions, demon-
strating that SIRT1 is a positive regulator of insulin gene expression.
2. Materials and methods
2.1. Reagents
Palmitate, resveratrol, and fatty acid-free bovine serum albumin
(BSA) were purchased from Sigma (St. Louis, MO, USA). RPMI 1640 me-
dium, fetal bovine serum(FBS), and other culture reagentswere obtained
from Gibco Life Technologies (Grand Island, NY). EX527 was from Tocris
Bioscience (Bristol, UK). Compound C was purchased from Calbiochem
(San Diego, CA). Rat insulin RIA kit and anti-SIRT1 antibody were pur-
chased from Millipore Technologies (Billerica, MA, USA). Anti-GAPDH,
anti-acetyl-p65, anti-p65, anti-acetyl-p53, anti-p53, and anti-mouse or
rabbit IgG conjugatedwith horseradish peroxidasewere fromCell Signal-
ing Technology (Beverly, MA, USA).
2.2. Cell culture
INS-1 cells (passage 22–35) were cultured in RPMI 1640 medium
with 11.1 mmol/L glucose, 10% FBS, 10 mmol/L HEPES, 2 mmol/L
L-glutamine, 1 mmol/L sodium pyruvate, 100 U/mL penicillin G sodi-
um, 100 μg/mL streptomycin sulfate, and β-mercaptoethanol (5 μl/L).
At 24 h before the experiment (24 h after seeding), themediumwas re-
placed with RPMI 1640 containing 5.6 mmol/L glucose or 16.7 mmol/L
glucose supplemented with either BSA alone or BSA coupled to palmi-
tate. The fatty acid coupling procedurewas performed as described pre-
viously [18]. This procedure generated BSA-coupled palmitate in a
molar ratio of 5:1 (generally, 0.4 mmol/L to 0.52% BSA, ﬁnal).
2.3. Rat infusions
The animal protocol was reviewed and approved by the Animal Care
Committee of Shanghai Jiaotong University School of Medicine. Male
Sprague Dawley rats (Shanghai Laboratory Animal Company, Shanghai,
China) weighing 250–300 g were housed under controlled temperature
(21 °C) and a 12-h light–dark cyclewith unrestricted access towater and
standard laboratory diet. The animals were randomized into two groups,
receiving 0.9% saline or 20% Intralipid with heparin (40 units/mL). The
infusion technique was similar to that described by Hagman et al. [19].
Under general anesthesia, indwelling catheters were inserted into the
right jugular vein. The catheterswere tunneled subcutaneously and exte-
riorized at the base of the neck. The animals were recovered for 5 days
after surgery. Catheter patency was maintained with 50 units/mL hepa-
rin in 0.9% saline. Intralipid and saline were infused at a constant rate
of 1 mL/h. After 24 h infusion, the animals were killed for islet isolation.
2.4. Islet isolation and treatment
Islets of Langerhans were isolated by in situ pancreas collagenase in-
fusion and separated by density gradient centrifugation [20] frommale
Sprague Dawley rats. The concentration of collagenase type XI was
0.5 mg/mL. Freshly isolated rat islets were transferred to 24-well plates
(10 islets per well) or 6-well (150 islets per well) plates and cultured
overnight in RPMI 1640 containing 5.6 mmol/L glucose, 10 mmol/L
HEPES, 100 U/mLpenicillin G sodium, and 100 μg/mL streptomycin sul-
fate supplementedwith either BSA alone or BSA coupled to palmitate at
37 °C and 5% CO2.2.5. Insulin secretion
Islets were washed once in Krebs-Ringer bicarbonate (KRB) buffer
[128.8 mmol/L NaCl, 4.8 mmol/L KCl, 1.2 mmol/L KH2PO4, 1.2 mmol/L
MgSO4, 2.5 mmol/L CaCl2, 5 mmol/L NaHCO3, and 10 mmol/L HEPES
(pH 7.4)] with 0.1% BSA containing 3.3 mmol/L glucose, and then
were preincubated for 30 min in 1 mL of the same medium at 37 °C.
This buffer was then replaced with 1 mL of prewarmed KRB containing
other additions as indicated for a further 60 min at 37 °C. An aliquot
was then removed for analysis of insulin secretion by RIA. Islets were
extracted with 0.18 N HCl in 70% ethanol for determination of insulin
content.
2.6. Western blotting
INS-1 cells or isolated islets in 6-well plates werewashed twicewith
ice-cold PBS and placed immediately in lysis buffer containing
25 mmol/L HEPES (pH 7.4), 1% Nonidet P-40, 100 mmol/L NaCl, 2%
glycerol, 5 mmol/L NaF, 1 mmol/L EDTA, 1 mmol/L Na3VO4, 1 mmol/L
NaPPi, 1 mmol/L phenylmethylsulfonyl ﬂuoride, 10 μg/mL aprotinin,
5 μg/mL leupeptin, and 5 μg/mL pepstatin. Lysates were gently mixed
for 10 min at 4 °C and then centrifuged at 13,000 g for 15 min at 4 °C.
The protein concentration of the extracts was determined according
to the method of Bradford, using BSA as the standard. Samples were
separated by SDS-PAGE on 8% polyacrylamide gels and transferred to
PVDF-Plus membranes (Bio-Rad, Hercules, CA). Primary antibodies
were detected with donkey anti-rabbit at 1:2000 for 1 h at room tem-
perature. Blottedmembranewas developedwith ECLAdvance (Cell Sig-
naling Technology, Boston,MA) and imagedwith a LAS-4000 Super CCD
Remote Control Science Imaging System (Fuji, JAP).
2.7. RNA isolation and real-time PCR
Total RNA was extracted from isolated islets or INS-1 cells using
Trizol (Invitrogen) according to the manufacturer's instructions. In
order to quantify the transcript abundance of genes of interest,
real-time PCR was performed using a SYBR Green Premix Ex Taq
(Takara, Shiga, Japan) with an Applied Biosystems 7300 Real-Time
PCR machine (Applied Biosystems, Foster City, CA). The results of
relative expression were normalized to β-actin mRNA levels in
each sample. The speciﬁc primers were as follows: SIRT1, 5′-AGG
GAACCTCTGCCTCATCTAC-3′ (forward), 5′-GGCATACTCGCCACCTAA
CCT-3′ (reverse); Insulin 1 (Ins1), 5′-CCTGCTCGTCCTCTGGGAGCCC
AAG-3′ (forward), 5′-CTCCAGTGCCAAGGTCTGAAGATCC-3′ (reverse);
Insulin 2 (Ins2), 5′-CCTGCTCATCCTCTGGGAGCCCCGC-3′ (forward), 5′-
CTCCAGTGCCAAGGTCTGAAGGTCA-3′ (reverse); neurogenic differentia-
tion (NeuroD), 5′-GGCTCCAGGGTTATGAGATC-3′ (forward), 5′-GCATT
CATGGCTTCAAGC-3′ (reverse); pancreatic and duodenal homeobox 1
(PDX1), 5′-CTTTCCCGAATGGAACCGAG-3′ (forward), 5′-GAATTCCTTCT
CCAGCTCC-3′ (reverse); NK6 homeodomain 1 (NKX6.1), 5′-CTATTCTCT
GGGGATGACGG-3′ (forward), 5′-TCTCGTCGTCAGAGTTCGGGTC-3′ (re-
verse); v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog A
(MafA), 5′-AGCAAGGAGGAGGTCATC-3′ (forward), 5′-CGTATTTCTCCTT
GTACAGG-3′ (reverse); and β-actin, 5′-AGGCCCCTCTGAACCCTAAG-3′
(forward), 5′-GGAGCGCGTAACCCTCATAG-3′ (reverse).
2.8. Plasmid transfection and siRNA interference
Transfection was conducted using Lipofectamine 2000 (Invitrogen)
according to themanufacturer'smanual. Brieﬂy, INS-1 cells were plated
in 24-well plates for 1 day before transfection. At 70–80% conﬂuency,
each well of cells was transfected with pECE-SIRT1, pcDNA3.1-PDX1,
pcDNA3.1-forkhead box O1 protein (FOXO1) or a control empty vector.
After 24 h of transfection, themediumwas changed for a further 24 h at
37 °C. SIRT1-speciﬁc small interfering RNA (siRNA) and negative con-
trol siRNA were designed and synthesized by Shanghai GenePharma
Fig. 1. Expression of SIRT1 in various mouse tissues and effect of fatty acids on its expression in rat islets in vivo. (A) Western blot analysis of SIRT1 expression in various mouse
tissues, isolated rat islets, MIN6 and INS-1 pancreatic β cell lines. (B) SIRT1 immunostaining of human and rat pancreatic sections. Immunoperoxidase staining labeled SIRT1 in
human pancreatic section. Immunoﬂuorescent staining labeled insulin (green) and SIRT1 (red) in rat pancreatic section. Rats were infused with 20% Intralipid for 24 h (n=5). Plas-
ma glucose (C) and insulin (D) levels were detected. Islets were isolated for SIRT1 mRNA (E) and protein (F) level assay by real-time PCR and Western blot. (G) After GK rats were
fed with high-fat diet for 10 weeks, islets were isolated for SIRT1 mRNA level assay by real-time PCR. Data are expressed as mean±SEM. *Pb0.05 vs. control group.
1817L. Wu et al. / Biochimica et Biophysica Acta 1822 (2012) 1815–1825
Fig. 2. Effects of fatty acids on SIRT1 expressions in INS-1 cells and rat islets in vitro. INS-1 cells and islets were incubated with the indicated concentrations of glucose in the pres-
ence or absence of 0.4 mmol/L palmitate for 24 h. The levels of SIRT1 mRNA (A) and protein (B and C) were detected by real-time PCR andWestern blot. (D and F) SIRT1 mRNA and
protein expressions in rat islets. (G) INS-1 cells were treated with 0.4 mmol/L palmitate in the presence or absence of 10 μmol/L resveratrol for 24 h. SIRT1 expression was detected
by Western blot. Data are expressed as mean±SEM for three separate experiments. *Pb0.05 vs. 5.6 mmol/L glucose; #Pb0.05 vs. 16.7 mmol/L glucose alone. A representative blot
from three independent experiments is shown. All three experiments showed similar results.
1818 L. Wu et al. / Biochimica et Biophysica Acta 1822 (2012) 1815–1825company and transiently transfected with siRNA using Lipofectamine
2000 as described above. The sequences of three SIRT1 siRNAs were as
follows: si-1, sense—CACCUGAGUUGGAUGAUAUTT, antisense—AUAU
CAUCCAACUCAGGUGTT; si-2, sense—CUGUGGCAGAUUGUUAUUATT,
antisense—UAAUAACAAUCUGCCACAGTT; and si-3, sense—GAUCAAG
AGAUGGUAUUUATT, antisense—UAAAUACCAUCUCUUGAUCTT.
2.9. Luciferase reporter assay
After INS-1 cells were plated in 24 well plates for 24 h, each well of
cells was transfectedwith 0.2 μg of rat insulin promoter (RIP) luciferase
plasmid. pRL-SV40 expressing Renilla luciferase (Promega) was used tonormalize the luciferase activity. Cells were harvested and luciferase ac-
tivity was measured using the Dual-Luciferase Reporter Assay System
(Promega).
2.10. Immunostaining
An adult human parafﬁn-embedded, formaldehyde-ﬁxed pancreatic
section from the Department of Pathology, Shanghai Ruijin Hospital,
and a rat frozen pancreatic section were blocked with 5% (wt/vol.) BSA
in PBS for 1 h. The human pancreatic section was incubated overnight
at 4 °C with rabbit anti-SIRT1 (1:100) and detected with biotinylated
anti-rabbit IgG in combinationwith streptavidin horseradish peroxidase.
Fig. 3. Resveratrol ameliorated palmitate-induced inhibition of glucose-stimulated insulin
secretion. (A) Isolated rat islets were pretreated with 0.4 mmol/L palmitate in the pres-
ence or absence of 10 μmol/L resveratrol at the indicated concentrations of glucose for
24 h, and then islets from each group were stimulated for 1 h in KRB buffer at 3.3 and
16.7 mmol/L glucose for insulin secretion assay. (B) Isolated rat islets were pretreated
with 10 μmol/L EX527 or 10 μmol/L compound C in the presence of 0.4 mmol/L palmitate
and 16.7 mmol/L glucose for 1 h, and then incubated with 10 μmol/L resveratrol for 24 h.
The islets from each group were stimulated for 1 h in KRB buffer at 3.3 and 16.7 mmol/L
glucose for insulin secretion assay. Data are expressed as mean±SEM for three separate
experiments. *Pb0.05 vs. 16.7 mmol/L glucose alone; #Pb0.05 vs. 16.7 mmol/L glucose
plus 0.4 mmol/L palmitate; ΔPb0.05 vs. 16.7 mmol/L glucose plus 0.4 mmol/L palmitate
and 10 μmol/L resveratrol.
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anti-SIRT1 (1:100) and guinea pig anti-insulin (1:400) primary anti-
bodies, and then detected with rhodamine-coupled anti-rabbit IgG and
FITC-labeled antiguinea pig IgG secondary antibodies.
HEK293 cells grown on glass coverslips were transfected with
HA-tagged FOXO1 plasmid for 24 h and treated as indicated. The cells
were ﬁxed in 4% (vol./vol.) paraformaldehyde for 15 min, permeabilized
with 2% (vol./vol.) Triton-X-100 for 10 min, and blocked in 5% (wt/vol.)
BSA for 1 h. Cellswere then incubated overnight at 4 °Cwithmonoclonal
anti-HA antibody (1:200) and stained with rhodamine-coupled anti-
rabbit IgG antibody. DAPI (Sigma-Aldrich) was used for nuclear staining.
The cellular localization of HA-tagged FOXO1 was photographed and
analyzed using a ﬂuorescence microscope (Olympus BX51; Olympus
America, Inc., Melville, NY).
2.11. Statistics
Data were presented as mean±SEM. Comparisons were performed
using ANOVA for multiple groups or the Student's t test for two groups.
Signiﬁcance was established at Pb0.05.
3. Results
3.1. SIRT1 is expressed in pancreatic β cells
To examine the connection between SIRT1 and β cell function, we
ﬁrst analyzed the tissue distribution of SIRT1 protein in C57BL/6
mice tissue. As shown in Fig. 1A, a moderate level of SIRT1 was
expressed in the pancreas compared to other tissues. SIRT1 was
highly expressed in the spleen, brain, and testis. Liver and fat tissues
showed comparable SIRT1 expression levels to that of the pancreas,
but a very low level of SIRT1 was detectable in skeletal muscle. In ad-
dition, SIRT1 expressions were also detected in primary islets isolat-
ed from rats, MIN6 and INS-1 pancreatic β cell lines. We further
immunostained SIRT1 on human and rat pancreatic sections with
an antibody against SIRT1. As in other cells reported previously
[21], SIRT1 was expressed in the nucleus of pancreatic β cells, not
in the cytoplasm (Fig. 1B).
3.2. Fatty acids decrease SIRT1 expression in INS-1 cells and isolated rat
islets in vivo and in vitro
To investigate whether SIRT1 is involved in pancreatic β cell
lipotoxicity, we ﬁrst examined its expression in isolated islets from
rats infused with Intralipid for 24 h. Plasma glucose and insulin levels
were increased in the Intralipid infusion group compared with the sa-
line infusion group (Pb0.05, Fig. 1C and D). SIRT1 mRNA level was de-
creased by 42% in islets of Intralipid-infused rats (Pb0.05, Fig. 1E).
SIRT1 protein expression showed a similar decrease (Fig. 1F). In isolated
islets of Goto–Kakizaki (GK) rats fed with a high-fat diet, SIRT1 mRNA
level was also decreased (Pb0.05, Fig. 1G). To detect the effect of fatty
acids on SIRT1 expression in vitro, INS-1 cells were exposed to
0.4 mmol/L palmitate for 24 h at a concentration of 16.7 mmol/L
glucose. SIRT1 mRNA and protein levels were signiﬁcantly reduced
by palmitate treatment (Fig. 2A and B). At the concentrations of
2.8, 5.6, and 16.7 mmol/L glucose, palmitate all decreased SIRT1 pro-
tein expression (Fig. 2C). We further examined SIRT1 expression in
isolated rat islets, and found a similar decline in palmitate-treated pri-
mary islets (Fig. 2D and E). However, 10 μmol/L resveratrol antagonized
palmitate-suppressed SIRT1 protein expression in INS-1 cells (Fig. 2F).
3.3. Resveratrol ameliorates palmitate-inhibited GSIS
The pattern of insulin secretion directly reﬂected the physiological
function of pancreatic islets. Here, insulin secretion was observed in is-
lets isolated from Sprague Dawley rats. As expected, GSISwasmarkedlydecreased after isolated rat islets were pretreated with 0.4 mmol/L pal-
mitate at a concentration of 16.7 mmol/L glucose, consistent with pre-
vious studies [6,22]. 10 μmol/L resveratrol had no effect on insulin
secretion in the presence of low glucose and palmitate while improved
GSIS suppressed by the combination of high glucose and palmitate
(Fig. 3A, Pb0.05). As it has been reported, resveratrol stimulates both
AMP-activated protein kinase (AMPK) and SIRT1 activities [23].We fur-
ther investigated which of AMPK and SIRT1 mediated resveratrol-
improved insulin secretion. Isolated rat islets were pre-incubated with
10 μmol/L compound C (an AMPK inhibitor) or 10 μmol/L EX527
(a SIRT1 inhibitor) for 1 h, and then co-incubated with 10 μmol/L
resveratrol for 24 h. Resveratrol-improved insulin secretion in the
presence of 0.4 mmol/L palmitate was abolished by EX527, not by
compound C. In addition, both EX527 and compound C had no sig-
niﬁcant effects on insulin secretion in the absence of resveratrol
compared with corresponding controls (Fig. 3B).
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Palmitate inhibits insulin gene transcription in the presence of high
glucose [3]. A reduction of SIRT1 expression under lipotoxic conditions
lead to a postulation that the inhibition of SIRT1 activity might be re-
sponsible for the defect of insulin gene transcription. To address this
question, we treated the INS-1 cells with EX527, which has shown po-Fig. 4. Inhibition of SIRT1 activity decreased insulin transcription. INS-1 cells were incubatedw
EX527 did not change SIRT1mRNA expression analyzed by real-time PCR. (B) The acetylated p6
assayed byWestern blot. (E) Insulin promoter activity was detected by the Dual-Luciferase Rep
were incubatedwith 10 μmol/L EX527 for 24 h, insulin 1 (INS1), insulin 2 (INS2), NeuroD, PDX-
expression was detected by Western blot. Data are expressed as mean±SEM for three indepetential and speciﬁc inhibition of SIRT1 [13,24]. Although EX527 did not
suppress SIRT1 mRNA expression (Fig. 4A), it dramatically enhanced
p65 and p53 acetylation, which are two well-known substrates for
SIRT1 [11,24]. On the contrary, resveratrol decreased p65 and p53 acety-
lation (Fig. 4B and C), suggesting that EX527 suppressed and resveratrol
stimulated SIRT1 activity. At the concentrations of 0.2, 0.4, and
0.8 mmol/L, palmitate increased p53 acetylation (Fig. 4D, Pb0.05).ith EX527, resveratrol or palmitate at the indicated concentrations for 24 h. (A) 10 μmol/L
5 (Ac-p65) level was assayed byWestern blot. (C and D) The acetylated p53 (Ac-p53)was
orter Assay System after SIRT1 activity was inhibited by EX527. (F and G) After INS-1 cells
1, NKX6.1, andMafAmRNA expressionswere detected by real-time PCR. (H) PDX1protein
ndent experiments. *Pb0.05 vs. control (CON).
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tions of 10 and 20 μmol/L (Fig. 4E, both Pb0.05). Furthermore,mRNAex-
pressions of Ins1, Ins2, and several transcription factors including MafA,
NKX6.1, and PDX1 were suppressed by 10 μmol/L EX527 (Fig. 4F and
G, all Pb0.05). Western blot also showed that EX527 decreased PDX1
protein expression (Fig. 4H).
To further characterize the roles of SIRT1, INS-1 cellswere transfected
with three siRNAs against SIRT1. As shown in Fig. 5A, SIRT1 protein levels
were reduced by about 50%. The knockdown of SIRT1 expression signif-
icantly inhibited RIP activity (Fig. 5B, Pb0.05). In addition,mRNA expres-
sions of Ins2, MafA, and NKX6.1 were also down-regulated. A tendency
toward decreased expressions, though not reaching signiﬁcance, was
also observed for Ins1 and PDX1 (Fig. 5C and D).3.5. Overexpression or activation of SIRT1 ameliorates palmitate-inhibited
insulin transcriptional activity
A previous study showed that SIRT1 could prevent interleukin-1β
and interferon-γ induced cytokine toxicity and maintain normal
insulin-secreting responses to glucose in isolated rat islets [25]. Res-
veratrol has been receiving increasing attention as a potent activator of
SIRT1 [26]. At the concentration of 16.7 mmol/L glucose, 10 μmol/L res-
veratrol dramatically increased RIP activity (Fig. 6A, Pb0.05). Hence,
we further investigated whether overexpression of SIRT1 could attenu-
ate the decline of insulin transcriptional activity under lipotoxicity. As
shown in Fig. 6B, 16.7 mmol/L glucose increased RIP activity compared
with 2.8 mmol/L, which was markedly decreased by 0.4 mmol/L palmi-
tate, consistent with previous studies [6,7]. Palmitate-suppressed insulinFig. 5. Knockdown of SIRT1 suppressed insulin transcription. (A) INS-1 cells were transfectedwi
protein expression was determined byWestern blot. (B) INS-1 cells were cotransfected with rat
sured using the Dual-Luciferase Reporter Assay System. (C and D) After INS-1 cells were transfec
(INS2), NeuroD, PDX-1, NKX6.1, and MafA mRNA expressions were detected by real-time PCR.
(CON).promoter activity was completely reversed by overexpression of SIRT1
and abrogated by resveratrol (both Pb0.05). Moreover, resveratrol
exerted a synergistic effect with SIRT1 overexpression on RIP activity in
the presence or absence of palmitate (Fig. 6C).3.6. SIRT1 enhances PDX1-stimulated and antagonizes FOXO1-inhibited
insulin promoter activity
PDX1 is a crucial factor required for the early development of pan-
creas and interacts synergistically with NeuroD and MafA to activate
the insulin promoter [27]. Thus, we examined the effect of SIRT1 on
the activity of PDX1 in the insulin promoter. SIRT1 exerted an additive
effect on PDX1 up-regulated RIP activity (Fig. 7A, Pb0.05). It has been
previously demonstrated that expression of a constitutively active mu-
tant of FOXO1 results in a complete lack of PDX-1 expression [28].
Fig. 7B showed that overexpression of FOXO1 inhibited insulin promot-
er activity, which was antagonized by SIRT1 overexpression (Pb0.05).3.7. Resveratrol abrogates palmitate-stimulated FOXO1nuclear translocation
It has been reported that palmitate stimulates FOXO1 nuclear trans-
location in MIN6 cells [29]. To detect whether resveratrol antagonize
this action, HEK293 cells were transfected with HA-tagged FOXO1 plas-
mid for 24 h, and incubated with 0.4 mmol/L palmitate and 10 μmol/L
resveratrol for 4 h. The results showed that resveratrol signiﬁcantly
suppressed palmitate-stimulated HA-tagged FOXO1 protein nuclear
translocation (Fig. 8A and B, Pb0.05).th three SIRT1 siRNAs (si-1, si-2, and si-3) or control scrambled siRNA (CON) for 48 h. SIRT1
insulin promoter plasmid and three SIRT1 siRNAs for 48 h. The luciferase activity was mea-
ted with SIRT1 siRNA or control scrambled siRNA for 48 h, SIRT1, insulin 1 (INS1), insulin 2
Data are expressed as mean±SEM for three independent experiments. *Pb0.05 vs. control
Fig. 6. SIRT1 antagonized palmitate-suppressed insulin promoter activity. (A) INS-1 cells
were transfected with the rat insulin promoter for 24 h, and then incubated with various
concentrations of resveratrol for 24 h. Dual-luciferase assay was performed. (B) INS-1 cells
were cotransfected with the rat insulin promoter and pECE-SIRT1 or empty vector for
24 h, and then media were changed with the indicated glucose concentration in the pres-
ence or absence of 0.4 mmol/L palmitate. Dual-luciferase assay was performed. (C) INS-1
cells were cotransfected with the rat insulin promoter and pECE-SIRT1 or empty vector
for 24 h, and then incubatedwith 0.4 mmol/L palmitate or 10 μmol/L resveratrol at the con-
centration of 16.7 mmol/L glucose. The dual-luciferase assay was performed. Data are
expressed as mean±SEM of three independent experiments. *Pb0.05 vs. control (basal or
without palmitate); #Pb0.05 vs. empty vector; ΔPb0.05 vs. palmitate alone.
Fig. 7. SIRT1 enhanced PDX1-stimulated and antagonized FOXO1-suppressed insulin pro-
moter activity. (A) INS-1 cells were cotransfected with the rat insulin promoter and the ex-
pression vectors pcDNA3.1-PDX1, pECE-SIRT1 or both at the concentration of 16.7 mmol/L
glucose for 24 h. The dual-luciferase assay was performed. (B) INS-1 cells were
cotransfectedwith the rat insulin promoter and the expression vectors pcDNA3.1-FOXO1,
pECE-SIRT1 or both for 24 h. The dual-luciferase assay was performed.*Pb0.05 vs. empty
vector. #Pb0.05 vs. pcDNA3.1-PDX1 or pcDNA3.1-FOXO1 alone. Data are expressed as
mean±SEM of three independent experiments.
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SIRT1 has been demonstrated to improve GSIS as evidenced by β
cell-speciﬁc SIRT1 overexpression transgenic mice [16]. A recent re-
port also revealed that overexpression of SIRT1 protected β cell
against cytokine toxicity [25]. Here we show that SIRT1 can protect
β cell against lipotoxicity induced by palmitate for the following rea-
sons. First, SIRT1 expression was signiﬁcantly decreased in isolated is-
lets from rats infused with Intralipid. Chronic exposure to palmitate
yielded a similar result in INS-1 cells and isolated islets in vitro. Second,
resveratrol improved palmitate-suppressed GSIS. Third, knockdown or
inhibition of SIRT1 suppressed insulin transcriptionwhile overexpression
or activation of SIRT1 ameliorated palmitate-inhibited RIP activity.
Circulating FFA levels are elevated in most patients of type 2 diabe-
tes, and it may be present for years and even decades [5]. Clearly,
long-term exposure to FFA induced insulin resistance [30]. In the light
of increased demands for insulin biosynthesis during insulin resistance
conditions, any inhibitory effect on insulin biosynthesis seems inappro-
priate and potentially deleterious. Therefore, protecting β cell against
Fig. 8. Resveratrol reversed palmitate-induced FOXO1 nuclear translocation. (A) HEK293 cells were transfected with HA-FOXO1 plasmid for 24 h, pretreated with 10 μmol/L res-
veratrol (RES) for 30 min, and then incubated with 0.4 mmol/L palmitate (PAL) for 4 h. Cellular localization of HA-tagged FOXO1 was detected by immunoﬂuorescence and
DAPI staining. (B) The number of cells with HA-tagged FOXO1 in the nucleus was counted (mean±SEM, n=600–1000 cells from three separate experiments). *Pb0.05 vs. control
(CON), #Pb0.05 vs. PAL alone.
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Skeletal muscle insulin resistance is a key component of the etiology
of type 2 diabetes. Many studies have shown that SIRT1 promotes insu-
lin sensitivity of skeletal muscle [17,31]. In this study, SIRT1 protein ex-
pression in pancreas was signiﬁcantly higher than in skeletal muscle,
suggesting that SIRT1 may also play an important role in the regulation
of isletβ cell function. β-cell‐speciﬁc SIRT1mice enhancedGSIS and im-
proved glucose tolerance after being fed with a high-fat diet [16]. Our
study showed that SIRT1 expressionwasmarkedly reduced in islets iso-
lated from rats infused with 20% Intralipid. The results were similar in
palmitate-treated INS-1 cells and isolated rat islets, which is consistent
with the results in C2C12myotubes reported previously [17].Moreover,
palmitate increased the acetylation level of p53, a target protein of
SIRT1, suggesting that palmitate inhibited SIRT1 activity. Resveratrol
antagonized the effect of palmitate on SIRT1 expression, suggesting
that SIRT1 may protect pancreatic β cell against lipotoxicity.
Resveratrol, a polyphenol compound, is known for its effects on en-
ergy homeostasis dependent or independent of SIRT1 [12,32,33]. Sever-
al papers have shown that resveratrol also stimulates AMPK in different
tissues [22,34,35]. Our previous studies showed that troglitazone acute-
ly inhibited GSIS via activating AMPK in MIN6 cells [36,37]. Chen et al.
[38] reported that resveratrol acutely enhanced insulin secretion by
blocking KATP and KV channels of β cells, while Szkudelski et al. [39]
displayed adverse results. Little is known about the long-term effect of
resveratrol on islet function. In the present study, we found thatresveratrol ameliorated palmitate-decreased insulin secretion, which
was abolished by a SIRT1 inhibitor, EX527, not by AMPK inhibitor com-
pound C. The result suggests that chronic resveratrol treatment poten-
tiates GSIS through a SIRT1-dependent pathway.
Transcriptional activation of insulin gene expression is a comprehen-
sive process. Palmitate impairment of insulin gene expression appears to
be mediated by direct inhibition of insulin promoter activity [7]. Insulin
promoter is mainly controlled in a 340 bp region upstream of the tran-
scription start site. Most of the responsiveness inherent to the insulin
promoter are conferred by the A3, E1 and C1 sites, which are bound by
the transcription factors PDX-1, NeuroD/Beta2, and MafA respectively.
These transcription factors act in a coordinated and synergistic manner
to stimulate insulin gene expression in response to increased glucose
levels [27]. Several studies showed that palmitate inhibited PDX-1 and
MafA expressions, and reduced PDX-1 nuclear localization, which con-
tribute to decreased insulin gene expression [7,40,41]. NKX6.1 is
known to be involved in pancreatic differentiation and beta cell func-
tion. Overexpression of NKX6.1 has been shown to increase GSIS in rat
islets [42]. In this study, the inhibition of SIRT1 activity by EX527 de-
creased insulin promoter activity and insulin mRNA expression, along
with decreased mRNA expressions of transcription factors PDX-1,
MafA, and NKX6.1. Knockdown of SIRT1 by siRNA veriﬁed the results.
Overexpression of SIRT1 or activation of SIRT1 by resveratrol abrogated
palmitate-inhibited insulin promoter activity. Moreover, the effect of
SIRT1 was additive to PDX1-increased insulin promoter activity. It has
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known acetyltransferase [43]. Hence, whether SIRT1 exerts its effects
by modulating the deacetylation of PDX1 needs to be determined.
Accumulating evidence indicates that the forkhead transcription fac-
tor FOXO1 serves as a negative regulator in pancreaticβ-cell dysfunction.
Inhibition of FOXO1 protects against fatty acid and endoplasmic reticu-
lum stress-induced β-cell apoptosis [29]. A gain-of-function FOXO1 mu-
tation targeted to liver and pancreatic β-cells results in diabetes, mainly
due to a combination of increased hepatic glucose production and
impaired β-cell compensation [44]. Pancreatic β-cells overexpressing
FOXO1 also show decreased glucose use and insulin secretion [45].
Knockdown of FOXO1 led to notable increases in the beta cell population
as well as insulin mRNA levels in human fetal islet epithelial cell clusters
[46]. Our study showed that FOXO1 overexpression inhibited glucose-
stimulated insulin promoter activity, which was antagonized by
overexpressing SIRT1. Recent studies have revealed that FOXO1 neg-
atively regulated PDX1 by modulating its subcellular localization
[27,47]. H2O2 and palmitate stimulated FOXO1 nuclear translocation
by Jun N-terminal kinase (JNK) pathway [28,29]. It is well-known that
FOXO1 is a substrate of SIRT1 [8]. In our study, resveratrol reversed
palmitate-stimulated FOXO1 nuclear translocation. Therefore, the inhi-
bition of FOXO1 may be one important mechanism underlying how
SIRT1 improves pancreatic β cell dysfunction.
RecentlyWuet al. [48] found that sirtinol, an inhibitor of SIRT1, atten-
uatedWldS (Wallerian degeneration slow)-induced activation of insulin
promoter. SIRT1was required for the improved insulin transcription and
secretion to streptozotocin-induced hyperglycemia caused byWldS. The
study of Park et al. [49] demonstrated that resveratrol inhibited phos-
phodiesterases, elevated cAMP level, and activated the cAMP effector
protein Epac (the exchange proteins activated by cyclic AMP) in C2C12
myotubes. Epac mediates stimulatory actions of the second messenger
cAMP on insulin secretion from pancreatic β cells [50]. Therefore, the
role of Epac in the regulation of resveratrol and SIRT1 on pancreatic β
cell function deserves further study.
Until now, little is known about the role of SIRT1 in islet function.
The suppression of uncoupling protein 2 is the only known explana-
tion for SIRT1-enhanced GSIS [15]. Our data demonstrate that SIRT1
activation ameliorates palmitate-suppressed GSIS and insulin tran-
scriptional activity, which may be attributed to the increased expres-
sions of β cell speciﬁc transcription factors.
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